Photoprotection expertise from Clinuvel

Written by on October 3, 2008 in melanotan with 0 Comments

Perhaps Clinuvel is best known as the Australian company that is developing Afamelanotide.

As some background: Melanotan is the proprietary name for afamelanotide (CUV1647) which is being development by Clinuvel Pharmaceuticals. Afamelanotide has been designated by the world health organisation as the International Nonproprietary Name for the melanocyte stimulating hormone under development by Clinuvel.

Clinuvel is promoting this drug as a photoprotective agent, firstly against the rare condition Erythropoietic Protoporphyria (EPP).

Clinuvel have an excellent web site dedicated to photoprotection – the conditions, current and future treatments, expert opinion and news updates.

If you are interested in ;

  • Actinic Keratosis (precancerous lesions of the skin)
  • Squamous Cell Carcinoma (malignant tumour of the skin)
  • Erythropoietic Protoporphyria (a rare inherited metabolic disorder of the heme pathway)
  • Polymorphous Light Eruption (a distressing seasonal skin condition likened to sun poisoning)
  • Photodynamic Therapy and Phototoxicity (phototoxicity after PDT treatment)
  • Solar Urticaria (anaphylactic reaction to sun)

then have a look at their excellent Photoprotection website.



Related Articles

Read more about: melanotan

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.